Correspondence 0001493152-23-024704 from Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)

Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Date: July 17, 2023 · CIK: 0001614067 · Accession: 0001493152-23-024704

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272128

Date

July 17, 2023

Author

Chief

Form

CORRESP

Company

Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)

Letter

Aridis Pharmaceuticals, Inc.

University Avenue, Bldg. B

Los Gatos, CA 95032

July 17, 2023

VIA EDGAR

United States Securities

and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Dillon Hagius

Re: Aridis Pharmaceuticals, Inc.

Form S-1

File No. 333-272128

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Aridis Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:15 p.m., Eastern Daylight Time, on Monday, July 17, 2023, or as soon thereafter as possible.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

Thank you,

ARIDIS PHARMACEUTICALS, INC.

By: /s/ Vu Truong

Name: Vu Truong

Title: Chief Executive Officer

-1-

Show Raw Text

CORRESP
1
filename1.htm

Aridis
Pharmaceuticals, Inc.

983
University Avenue, Bldg. B

Los
Gatos, CA 95032

July
17, 2023

VIA
EDGAR

United
States Securities

and
Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Dillon Hagius

  Re:
  Aridis Pharmaceuticals,
  Inc.

  Form S-1

  File No. 333-272128

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Aridis Pharmaceuticals,
Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated
so that it will become effective at 5:15 p.m., Eastern Daylight Time, on Monday, July 17, 2023, or as soon thereafter as possible.

Please
notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible
as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

    Thank
    you,

    ARIDIS
    PHARMACEUTICALS, INC.

    By:
    /s/
    Vu Truong

    Name:
    Vu
    Truong

    Title:
    Chief
    Executive Officer

    -1-

SecProbe.io